Regenerex sues former CFO Perry for alleged $55K overpayments, $37K overcharges, stock theft

REGENEREX PHARMA, INC.

Complaint filed June 5, 2026, in Smith County Chancery Court (Case No. 2026-CV-8813).
Alleges former CFO Perry caused unauthorized payroll overpayments totaling ~$55,200 over six months.
Perry's company Optimize Health overbilled $136,056; includes alleged 30% administrative fee of ~$37,285.
Perry authorized 25,000 shares of common stock to a trust without board approval, then canceled.
Company says Perry's conduct caused delayed Form 10-K filing and substantial audit/remediation costs.

item 5.02 item 9.01

Featured in Daily 8-K Digest

Selected #6 for 2026-06-11. Read digest

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kenneth W. Perry

Chief Financial Officer

RGPX · REGENEREX PHARMA, INC.

Filed: June 11, 2026, 1:52 PM ET

As of June 5, 2026, the Company has commenced legal proceedings against its former Chief Financial Officer, Kenneth W. Perry (the "Former CFO"), in the matter of Regenerex Pharma, Inc. v. Kenneth W. Perry , Smith County Chancery Court, Case No. 2026-CV-8813.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth W. Perry departed as Chief Financial Officer at REGENEREX PHARMA, INC..

Role: Chief Financial Officer

Exact text from the filing

As of June 5, 2026, the Company has commenced legal proceedings against its former Chief Financial Officer, Kenneth W. Perry (the "Former CFO"), in the matter of Regenerex Pharma, Inc. v. Kenneth W. Perry , Smith County Chancery Court, Case No. 2026-CV-8813.

View on SEC.gov

REGENEREX PHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001472375-26-000167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.